据知情人士透露,诺和诺德(NVO.US)与Hims & Hers Health Inc.(HIMS.US)即将握手言和,计划最早于周一宣布全新合作协议,这家丹麦制药商将授权在Hims平台销售其减肥药物,从而终结双方的公开对峙。受此消息提振,Hims股价在美股盘前一度暴涨55%,而诺和诺德则上涨约1%。据了解,双方曾在去年达成类似协议,但因Hims拒绝停止营销仿制药品,诺和诺德随即单方面终止合作。
据知情人士透露,诺和诺德(NVO.US)与Hims & Hers Health Inc.(HIMS.US)即将握手言和,计划最早于周一宣布全新合作协议,这家丹麦制药商将授权在Hims平台销售其减肥药物,从而终结双方的公开对峙。受此消息提振,Hims股价在美股盘前一度暴涨55%,而诺和诺德则上涨约1%。据了解,双方曾在去年达成类似协议,但因Hims拒绝停止营销仿制药品,诺和诺德随即单方面终止合作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.